Nivolumab 100mg/10ml Injection

Nivolumab is a PD-1 inhibitor monoclonal antibody antineoplastic for melanoma and lung cancer, supplied in 100mg/10ml preservative-free vials. It meets HTS 3004.90.92.16 criteria for measured-dose immunosuppressive biologics.

Import Duty Rates by Country of Origin

Origin CountryMFN RateCh.99 SurchargesTotal Effective Rate
🇨🇳ChinaFreeFree
🇲🇽MexicoFreeFree
🇨🇦CanadaFreeFree
🇩🇪GermanyFreeFree
🇯🇵JapanFreeFree

Alternative Classifications

This product could be classified differently depending on its characteristics or intended use.

3002.13.00Same rate: Free

If classified as direct immunological regulator

Chapter note 2 includes antibody conjugates under 3002 immunological products.

3004.90.92Same rate: Free

If other antineoplastics excluding specific immunosuppressants

Statistical suffixes differentiate within the antineoplastic category.

Not sure which classification is right?

Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.

Import Tips & Compliance

,Use data loggers for full shipment temperature excursion proof

Related Products under HTS 3004.90.92.16

Tacrolimus 1mg Capsules

Tacrolimus capsules are immunosuppressive medicaments used to prevent organ transplant rejection, containing 1mg of the active ingredient in hard gelatin capsules for oral measured doses. Classified under HTS 3004.90.92.16 for retail-packed immunosuppressive products.

Mycophenolate Mofetil 500mg Tablets

Mycophenolate mofetil is an immunosuppressive prodrug inhibiting lymphocyte proliferation, used post-transplant in 500mg enteric-coated tablets. Under HTS 3004.90.92.16 for retail-packaged measured medicaments.

Pembrolizumab 100mg/4ml Solution

Pembrolizumab injection is an anti-PD-1 antineoplastic monoclonal antibody for various cancers, in 100mg/4ml vials for IV infusion. HTS 3004.90.92.16 applies to these dosed immunosuppressive therapies.

Imatinib Mesylate 400mg Tablets

Imatinib mesylate tablets are an antineoplastic medicament used primarily for treating chronic myeloid leukemia by inhibiting tyrosine kinase activity. They are put up in measured doses of 400mg per tablet in retail packaging, qualifying under HTS 3004.90.92.16 as an unmixed antineoplastic product for therapeutic use.

Cyclophosphamide 50mg Injection Vials

Cyclophosphamide is an immunosuppressive and antineoplastic agent used in chemotherapy for cancers and autoimmune diseases, supplied in sterile 50mg vials for measured dosing. It fits HTS 3004.90.92.16 as a put-up unmixed product for therapeutic retail sale or hospital use.

Rituximab 100mg/10ml Intravenous Infusion

Rituximab is a monoclonal antibody antineoplastic used for non-Hodgkin lymphoma and rheumatoid arthritis, provided in 100mg/10ml single-use vials for measured IV administration. It qualifies under HTS 3004.90.92.16 as an immunosuppressive biologic in dosed form.